Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Oncopeptides

1.58 SEK

-0.38 %

Less than 1K followers

ONCO

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.38 %
-39.70 %
-65.24 %
-68.66 %
-68.60 %
+19.08 %
-75.74 %
-98.45 %
-94.22 %

Oncopeptides is a biotechnology company developing drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic agents into cancer cells. The company has drugs for commercialization, and has several drug candidates in development. Oncopeptides was founded in 2000 and is headquartered in Stockholm.

Read more
Market cap
633.54M SEK
Turnover
2.78M SEK
Revenue
71.12M
EBIT %
-315.87 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.5
2026

Interim report Q1'26

21.5
2026

General meeting '26

27.8
2026

Interim report Q2'26

All
Webcasts
Press releases
3rd party
ShowingAll content types
Press release19 hours ago

Oncopeptides secures fast-track designation for Window-of-Opportunity study in glioblastoma

Oncopeptides
Regulatory press release2/26/2026, 7:30 AM

Oncopeptides publishes disclosure document regarding rights issue

Oncopeptides
Press release2/20/2026, 12:54 PM

Redeye: Oncopeptides (Q4 Update): Political Risk in Spain and a Slower Germany

Oncopeptides

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Oncopeptides, Audiocast, Q4'25
Webcast2/19/2026, 8:00 AM

Oncopeptides, Audiocast, Q4'25

Oncopeptides
Regulatory press release2/19/2026, 7:00 AM

Oncopeptides publishes year-end report 2025

Oncopeptides
Regulatory press release2/19/2026, 6:58 AM

Oncopeptides carries out a rights issue of approximately SEK 200 million

Oncopeptides
Press release2/12/2026, 7:30 AM

Invitation to presentation of the year-end report 2025

Oncopeptides
Oncopeptides, Audiocast, Investor Conference, 2026
Webcast1/16/2026, 8:00 AM

Oncopeptides, Audiocast, Investor Conference, 2026

Oncopeptides
Regulatory press release1/15/2026, 6:00 PM

Oncopeptides announces Q4 2025 sales and updates cash-flow expectations

Oncopeptides
Press release12/29/2025, 9:00 AM

Research shows that Pepaxti is effective in high-risk myeloma

Oncopeptides
Regulatory press release11/21/2025, 7:30 AM

Oncopeptides announces the Nomination Committee

Oncopeptides
Oncopeptides, Capital Markets Update, 2025
Webcast11/13/2025, 8:00 AM

Oncopeptides, Capital Markets Update, 2025

Oncopeptides
Press release11/11/2025, 7:30 AM

Annals of Hematology: Expert consensus supports use of Pepaxti in myeloma

Oncopeptides
Press release11/7/2025, 7:39 AM

Redeye: Oncopeptides (Q3 Update) - Q/Q Growth Only 5%, but 2026 Looks Promising

Oncopeptides
Oncopeptides, Audiocast, Q3'25
Webcast11/5/2025, 8:00 AM

Oncopeptides, Audiocast, Q3'25

Oncopeptides
Regulatory press release11/5/2025, 7:00 AM

Oncopeptides publishes Q3 report 2025

Oncopeptides
Press release11/3/2025, 2:30 PM

Research by top universities together with Oncopeptides on NK cell engagers to be presented at ASH

Oncopeptides
Regulatory press release10/31/2025, 7:30 AM

Number of shares and votes in Oncopeptides

Oncopeptides
Press release10/29/2025, 7:30 AM

Invitation to presentation of the Q3 report 2025

Oncopeptides
Press release10/22/2025, 3:30 PM

Oncopeptides to host Capital Markets Update featuring leading global experts in Multiple Myeloma

Oncopeptides
Forum discussions
Oncopeptides AB is a Swedish biotech company that, after a long development phase, has successfully developed and commercialized a drug called Pepaxti. This drug is intended for use in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have...
1/1/2026, 6:25 PM
by Hawkmountdiver
6
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.